Avecho successfully completes recruitment for interim analysis on pivotal Phase III trial
Avecho has completed recruitment for the interim analysis cohort of participants for its pivotal Phase III clinical trial evaluating its TPM® -enhanced cannabidiol (CBD) capsule for insomnia.
The Company has successfully enrolled the approximately 210 participants required for the planned interim analysis, which will provide the first indication of efficacy, materially de-risk the program moving forward and confirm the number of participants required to complete the study.
Results are anticipated in June 2026 and represent a major value-defining catalyst for the Company.
Avecho CEO, Dr Paul Gavin, said:
“Completing recruitment for the interim analysis cohort marks a significant inflection point for the Phase III program and brings us within sight of a long-anticipated result supporting the efficacy of our product.
“With a commercial partnership with Sandoz already in place for Australia, the upcoming interim analysis represents a potentially transformative catalyst for Avecho that puts the Company in an excellent strategic position moving forward. A positive outcome would materially de-risk the program and increase its attractiveness to prospective partners around the world.”